In the Conexión Binding Site cycle, Uruguayan hematologist Dr. Eloisa Riva was interviewed by Dr. Florencia Delgado and Dr. Elisa Barroeta, scientific directors of Binding Site Latam.
As a member of the Latin American Study Group on Multiple Myeloma (GELAMM), Dr. Riva talks about the importance of timely diagnosis, the situation in Uruguay and the work of the group in Latam.
Among the main challenges identified in our country are the nonspecific symptoms that may delay the patient's consultation or the indication of the corresponding study by the attending physician, as well as the need to have more information on the prevalence of monoclonal gammopathies in the Uruguayan population in general to be able to know early those asymptomatic cases.
"Patients who come from a monoclonal gammopathy of unknown significance are generally treated earlier and have better results at the organ level," says Dr. Riva. In this sense, a prevalence study that is already underway could allow us to know "who would be recommended to do a routine protein study, as is done today with mammography."
You can access the full interview here:
We also invite you to watch the interview with our Commercial Director, Gabriel Pastoriza, in this same cycle of Conexión Binding Site, CLICKING HERE.
